ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Offers Bibliography On Risk Communication.

March 23, 2001

NIH Inquiry Finds No Impropriety In Treatment of Teddy DeVita

April 9, 1976

Two Cooperative Groups Renamed ECOG-ACRIN

September 23, 2011

In Brief Yale Cancer Center Begins Reorganization, Names New Deputy Director, Prevention Chief

January 6, 1995

PhRMA Tightens DTC Restrictions, But Dingell Says It’s Not Enough.

December 12, 2008

In Brief: Thomas, Murray share Nobel Prize for Medicine; Wynder To Present Carese Memorial Lecture

October 12, 1990